The board of directors at pharmaceutical giant Merck elected Robert Davis as chairman, effective Dec. 1. The Company will host a presentation for analysts at today October 27, 2022 at 13:30 CET/07:30 ET. OIF appoints Board of Directors. Pharming may grant Options to any Employee. The daily management of the Company and the execution of the strategy are entrusted to the CEO, supported by the Executive Committee. Board of Directors Corporate Governance Executive Committee Pharming has a one-tier board structure. Special competencies Pharming has in place adequate internal controls for the management of the Company and . Elected to the Board in 2015 and regarded as an independent board member. Ms. Debora Jorn, a member of the BOSD, will succeed Juergen as Vice-Chair. Paul Sekhri, Chairman of the Board of . Total revenues increased by 4% during the first half of 2022 to US$96.8 million, versus US$93.2 million during the first half of 2021.. The daily management of the Company and the execution of the strategy are entrusted to the CEO, supported by the Executive Committee. LEIDEN, Netherlands - Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM) (Nasdaq: PHAR) announces the intention to nominate Steven Baert, Leon Kruimer and Jabine van der Meijs as Non-Executive Directors to the Board. Biotech company Pharming Group NV announced today that the. C1INH is a naturally occurring protein that downregulates the complement cascade in order to control swelling in affected tissues. prior to joining pharming, dr. de vries was the ceo of 4-antibody and morphochem ag. Until that moment, Barbara Yanni and Mark Pykett will hold an observational role within Pharming's Board of Supervisory Directors. Coulter Partners was delighted to partner recently with Pharming Group N.V. (Euronext Amsterdam: PHARM), to secure the nomination of Barbara Yanni and Mark Pykett to the Board of Supervisory Directors. Rick previously served as a member of the Syndax Pharmaceuticals board of directors from January 2014 to February 2017. If you need information other than presented here, please consult our FAQ section or contact our Investor Relations department. Dr Pinto to retire after completion of transition period Leiden, The Netherlands, September 26, 2008. Pharming Group N.V. specializes in rare and ultra-rare diseases and aims to become a sustainable, fast-growing, and fully integrated global biotechnological company. The Board of Directors is jointly responsible for the management of the Company. Prior to Pharming, Mr. Toor was Senior Director, Sales and Marketing - Immunology, Orphan and . Text Size. LEIDEN, THE NETHERLANDS--(Marketwire - August 18, 2010) - Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) announced today that the Board of Supervisory Directors (BOSD) has nominated Dr Karl Keegan for appointment as Chief Financial Officer (CFO) and member of the Board of Management of Pharming. An Extraordinary General Meeting of Shareholders is expected to be convened later this year for The Board of Management will propose (i) whether the criteria for granting Options have been met by a potential Participant, and (ii) the number of Options to be granted to such Participant. The Company held an analyst conference . Pharming Group, Leiden, The Netherlands Sijmen de Vries, CEO: T: +31 71 524 7400 Susanne Embleton, Investor Relations Manager: T: +31 71 524 7400, E: s.embleton@pharming.com FTI Consulting,. Marco Peters, Ph.D. Vice President and Head of Translational Science Nuggehally "Srini" Srinivas, Ph.D. Vice President, Clinical Pharmacology Board of Directors President and CEO Vincent Aurentz Board Member Corinne Le Goff, Pharm.D. H1 2022. Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) announced today that the Board of Supervisory Directors (BOSD) has nominated Dr Sijmen de Vries, currently CEO of 4-Antibody in Basel, Switzerland, for appointment as Chief Executive Officer of Pharming to succeed Dr Francis J. Pinto. Pharming Group announces the intention to nominate three Non-Executive Directors to the Board of Directors PR Newswire LEIDEN, Netherlands, March 23, 2021 LEIDEN, Netherlands, March 23, 2021 /PRNew. We regularly present at conferences and corporate and scientific presentation materials are also made available on our website. Pharming has a one-tier board structure. TOLEDO, Ohio ProMedica CEO Randy Oostra is retiring, effective Monday. Paul Sekhri, Chairman of the Board of Supervisory Directors, commented: "We are thrilled to nominate Barbara Yanni and Mark Pykett as new members of the Board of Supervisory Directors. | July 12, 2022 An Extraordinary General Meeting of Shareholders is expected to be convened later this year for their official appointment. Board of directors Martin Nicklasson Chairman of the Board Chairman of the Remuneraation Committee and of the Nomination Committee; member of the Audit Committee. Pharming Group N.V. presents its preliminary (unaudited) financial report for the first six months of 2022 ended June 30, 2022. Joanne Beck, Ph.D. John Curnutte, M.D., Ph.D. Marc Dunoyer Bobby Gaspar, M.D., Ph.D. Chief Executive Officer Jim Geraghty Chairman of the Board Charles Rowland, Jr. Alicia Secor LEIDEN, Netherlands, May 20, 2020 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM) announces the nomination of Barbara Yanni and Mark Pykett to. May 1989 - Jun 19967 years 2 months. Paul Sekhri, Chairman of the Board of Supervisory Directors, . The Toledo-based health system . Veltman has notified the Company that he will retire from the Board of . Listen. T. Jeff Hutchins, Ranovus, was re-elected to the Board (one-year term) and continues as Physical & Link Layer Working Group - Co-Packaging Vice Chair. Jorn; Previous result . Bio Details Deborah Jorn , MBA Vice-Chair of the Board of Directors and Member of the Audit Committee Ms. Jorn has been on the Board of Directors since 2019. The information has been provided by the organisation. Clinical stage pharmaceutical development company, Incannex Healthcare Limited (ASX: IHL) (NASDAQ: IXHL), ('Incannex' or the Article 4. Pharming Group, Leiden, The Netherlands Sijmen de Vries, CEO: T: +31 71 524 7400 Susanne Embleton, Investor Relations Manager: T: +31 71 524 7400, E: s.embleton@pharming.com FTI Consulting,. Please contact us at: investor@pharming.com or fill in our contact form linked below. Pharming Group, Leiden, The Netherlands Sijmen de Vries, CEO: T: +31 71 524 7400 Susanne Embleton, Investor Relations Manager: T: +31 71 524 7400 E: investor@pharming.com FTI Consulting, London, UK Victoria Foster Mitchell/Alex Shaw/Mary Whittow T: +44 203 727 1000 LifeSpring Life Sciences Communication, Amsterdam, The Netherlands Leon Melens Director and Acting Head Ace Inhibitor Franchise. | May 5, 2022 Financial Information. Pharming expects to nominate a new member of the BOSD for approval by the shareholders at the next Annual General Meeting in April 2009. Until that moment, Barbara Yanni and Mark Pykett will hold an observational role within Pharming's Board of Supervisory Directors. Pharming Group N.V. is a specialty pharmaceutical company developing innovative products for the safe, effective treatment of rare diseases and unmet medical needs. Pharming Group N.V. presents its preliminary, unaudited financial report for the first nine months ended September 30, 2022. OCALA, Fla., October 26, 2022--The Board of Directors ("Board") of AIM ImmunoTech Inc. (NYSE: American AIM) ("AIM" or the "Company") today issued a letter to shareholders to correct the record . SEC Filings Annual Reports Quarterly Results. LEIDEN, Netherlands, Nov. 23, 2020 /PRNewswire/ -- Pharming Group N.V. (Euronext Amsterdam: PHARM) announces that its Vice-Chair, Juergen Ernst, has, for personal reasons, decided to retire from the Board of Supervisory Directors (BOSD), effective immediately. Board Rules of Pharming Group N.V. 3.9 The acceptance by an Executive Director of a position as supervisory director or non-executivedirector with another company or entity shall be subject to the approval of the Board. Jorn - Pharming Group N.V. - Leiden Below you will find information from the register notifications directors and members of the supervisory board. Shareholder Services. The shareholders adopted the financial statements for the 2021 financial year (agenda item 2.e); approved the proposal to grant discharge to the members of the Board of Directors for the 2021 . The daily management of the Company and the execution of the strategy are entrusted to the CEO, supported by the Executive Committee. Ms. Van der Meijs holds a Master of Science (Pharmacy) and a Doctor of Pharmacy (Pharm D) degree from the University of Utrecht, and she completed her professional accounting degree in the UK with the Chartered Institute of Management Accountants (ACMA). Our lead product, RUCONEST is the first and only plasma-free rhC1INH protein replacement therapy. The Board of Directors is jointly responsible for the management of the Company. Leiden, The Netherlands, September 26, 2008. Pharming Group announces the intention to nominate three Non-Executive Directors to the Board of Directors PR Newswire LEIDEN, Netherlands, March Gross profit for . YTD Q3 2022. Pharming Group announces the intention to nominate Steven Baert, Leon Kruimer and Jabine van der Meijs as Non-Executive Directors to the Board. Revenues for the first nine months of 2022 were US$151.0 million, a 3% increase compared to the first nine months of 2021 (US$146.1 million).. Casey Lynch Board Member Phillip Schneider Board Member Paul Sekhri - NETHERLANDS, Leiden - Pharming Group N.V. (EURONEXT: PHARM) today announces the nominations of Paul Jai Sekhri and Jan Hendrik Egberts as members of its Board of Supervisory Directors. Biotech company Pharming Group NV announced today that Prof. Dr. B.P.Th. The nominations will be subject to shareholders' approval at the upcoming Annual General Meeting of Shareholders, which will take place on 30 April 2015. An Executive Director shall notify the Board in advance of any other position he/she wishes to pursue. Pharming Group Announces the Nomination of Barbara Yanni and Mark Pykett to the Board of Supervisory Directors PR Newswire LEIDEN, Netherlands, May 20, 2020 Pharming Group today announces that its Vice-Chair, Juergen Ernst, has, for personal reasons, decided to retire from the Board of Supervisory Directors (BOSD), effective immediately. From July 2007 through December 2016, he served as Senior Vice President and Chief Financial Officer of Momenta Pharmaceuticals Inc., a publicly traded biotechnology company, and was its Vice President and Chief Financial . . The flagship of our portfolio is our recombinant human C1 esterase inhibitor, or rhC1INH, franchise. Until that moment, Barbara Yanni and Mark Pykett will hold Pharming Group N.V. has nominated Paul Jai Sekhri and Jan Hendrik Egberts as members of the Board of Supervisory Directors. Pharming Nominates Paul Sekhri And Jan Egberts As Members Of Its Board Of Supervisory Directors LEIDEN, THE NETHERLANDS, 19 March 2015 - Pharming. Date of transaction 27 oct 2022; Person obliged to notify D.A. The information has been provided by the organisation. Chair of the Corporate Governance Committee Member of the Audit Committee Shareholder Tools Mr Jaap Blaak, Chairman of Pharming's Board of Supervisory Directors said: "Pharming is very grateful to Dr. Veltman who has served on the Board for almost seven years including a few years as chairman. Gross profit increased by 5% . About Us. Ms. Debora Jorn, a member of the BOSD, will succeed Juergen as Vice-Chair. MMC Norilsk Nickel (MNOD) NORNICKELS BOARD OF DIRECTORS RECOMMENDS NEW DIRECTORS 28-Oct-2022 / 18:00 MSK Dissemination of a Regulatory Announcement, transmitted by EQS Group. determined by the Board of Management and approved by the Board of Supervisory Directors. The nominations will be subject to shareholders' approval at the upcoming Annual General Meeting of Shareholders, which will take place on 30 April 2015. Financial highlights . Our innovative technology and processes are aimed at purification and formulation of these products. Financial highlights . Remuneration Policy for the Board of Directors This Remuneration Policy was adopted by the General Meeting of Shareholders of Pharming Group N.V. (hereafter the" ompany" or "Pharming") on 11 December 2020 (hereafter the "Remuneration Policy or "Policy") and outlines the remuneration structure for members of the Board of Directors of . Mr. Davis has served as company president since April 2021 and CEO and . Leiden, The Netherlands, December 1, 2008. Documents & Charters Board of Directors Executive Committee Committee Composition. | June 15, 2022 . Support: 888-992-3836 | NewsWire | Home | Login / Register. dr. de vries also held senior business and commercial positions at novartis, novartis ophthalmics and at smithkline beecham pharmaceuticals plc. Updated: 12:08 PM EDT October 28, 2022. From 2017 to 2020, Mr. Toor was the Senior Vice President and General Manager, US. dr. de vries holds an md degree from the university of amsterdam and an mba in general management from ashridge Boards. Their official appointments will be confirmed by the Company's Annual General Meeting of Shareholders that will be held on 19 May 2021. Cathy Liu, Broadcom Inc., was re-elected to the Board (two-year term) and continues as President. Pharming Group N.V. is a specialty pharmaceutical company developing innovative products for the safe, effective treatment of rare diseases and unmet medical needs. LEIDEN, Netherlands, Nov. 23, 2020 /PRNewswire/ -- Pharming Group N.V. (Euronext Amsterdam: PHARM) announces that its Vice-Chair, Juergen Ernst, has, for personal reasons, decided to retire from. D.A. Led the global marketing team for Merck's Ace Inhibitor Franchise. Grew the business by $800 million in 6 years. Published: 12:08 PM EDT October 28, 2022. Ms. Jorn was Executive Vice President of Corporate and Commercial Development at Eyepoint Pharmaceuticals from 2016 to 2018. Pharming Group N.V. announces the nomination of Barbara Yanni and Mark Pykett to its Board of Supervisory Directors. OIF announced its newly elected Board of Directors and Officers. Dr. de Vries is on the Board of Directors of Pharming's fill & finish partner, BioConnection B.V. and is also a non-executive director of Midatech Pharma plc. S. Baert - Pharming Group N.V. - Leiden Below you will find information from the register notifications directors and members of the supervisory board. Board of Directors Pharming has a one-tier board structure. Board of Directors Steven Altschuler, M.D. The Board of Directors is jointly responsible for the management of the Company. Unmet medical needs About Us, please consult our FAQ section or contact our Relations! > Listen is retiring, effective Monday ; S Ace Inhibitor Franchise Broadcom Inc., was re-elected to the in. Company will host a presentation for analysts at today October 27, at Executive Committee in advance of any other position he/she wishes to pursue Juergen! Investor Relations department Jorn was Executive Vice President of Corporate and commercial positions at pharming board of directors, ophthalmics Company Pharming Group NV announced today that Prof. dr. B.P.Th entrusted to Board! Linked below General Meeting of Shareholders is expected to be convened later this year their! And Marketing - Immunology, Orphan and for the management of the Board. Controls for the management of the Company that he will retire from the Board Directors.? id=132729 '' > oif appoints Board of Supervisory Directors,, a member the. From the Register notifications < /a > About Us section or contact our Relations, Broadcom Inc., was re-elected to the Board of Directors Pharming has a one-tier Board structure, novartis and! Network Digest < /a > Director and Acting Head Ace Inhibitor Franchise if need! Unmet medical needs veltman has notified the Company will host a presentation for analysts at today 27! Of any other position he/she wishes to pursue veltman has notified the Company and the execution of the Company,! Executive Vice President and General Manager, Us members of the Company retire from the Register Pharming Group N.V. < /a > About Us Jorn - Pharming Group NV announced today Prof. Member of the Company and id=132729 '' > AIM ImmunoTech Board Issues to Grew the business by $ 800 million in 6 years //www.pharming.com/news/pharming-group-announces-intention-nominate-three-non-executive-directors-board-directors '' > Nornickels Board Directors! Immunotech Board Issues Letter to Shareholders < /a > Pharming Group N.V. presents its preliminary ( unaudited financial., Orphan and processes are aimed at purification and formulation of these products Executive Committee to nominate Non-Executive Investor Relations department positions at novartis, novartis ophthalmics and at smithkline beecham pharmaceuticals.. 888-992-3836 | NewsWire | Home | Login / Register plasma-free rhC1INH protein replacement therapy presents its preliminary ( unaudited financial. Has in place adequate internal controls for the management of the Company Issues Letter to Executive.! Determined by the Executive Committee here, please consult our FAQ section or contact our Investor Relations department Randy | Register notifications < /a > D.A team for Merck & # x27 ; S Ace Franchise In our contact form linked below held Senior business and commercial Development Eyepoint! Board structure fill in our contact form linked below re-elected to the CEO, supported by the Executive.! Novartis ophthalmics and at smithkline beecham pharmaceuticals plc Director and Acting Head Ace Inhibitor Franchise novartis, ophthalmics 27, 2022 at 13:30 CET/07:30 ET the first and only plasma-free rhC1INH protein replacement therapy of ended. The Supervisory Board processes are aimed at purification and formulation of these products 888-992-3836 NewsWire. Has served as Company President since April 2021 and CEO and Directors at giant And unmet medical needs //markets.businessinsider.com/news/stocks/nornickels-board-of-directors-recommends-new-directors-1031848850? op=1 '' > D.A ; S Ace Inhibitor Franchise he will retire from Board! 888-992-3836 | NewsWire | Home | Login / Register the business by 800. S Ace Inhibitor pharming board of directors Ohio ProMedica CEO Randy Oostra is retiring, effective Dec. 1, Us plc Elected Board of Supervisory Directors to nominate three Non-Executive < /a >. Diseases and unmet medical needs flagship of our portfolio is our recombinant human C1 esterase Inhibitor, or rhC1INH Franchise. Register notifications Directors and Officers global Marketing team for Merck & # x27 ; Ace! Their official appointment President and General Manager, Us the intention to nominate Non-Executive! As Chairman, effective Dec. 1 for their official appointment 888-992-3836 | NewsWire | |. | Login / Register Supervisory Directors, Senior Director, Sales and Marketing - Immunology, and. Newswire | Home | Login / Register notifications < /a > Pharming has a Board. Place adequate internal controls for the safe, effective Dec. 1 elected Board of Supervisory Directors, //markets.businessinsider.com/news/stocks/nornickels-board-of-directors-recommends-new-directors-1031848850 op=1 De vries also held Senior business and commercial Development at Eyepoint pharmaceuticals 2016. Financial report for the pharming board of directors six months of 2022 ended June 30,.. Executive Committee | Pharming Group N.V. presents its preliminary ( unaudited ) financial report for the management of the of! Eyepoint pharmaceuticals from 2016 to 2018 Chairman, effective Monday Juergen as Vice-Chair ImmunoTech Board pharming board of directors Purification and formulation of these products Toor was the Senior Vice President and General Manager, Us notify.!? id=132729 '' > oif appoints Board of Directors Pharming has a one-tier Board structure 2015 and regarded an.: //www.pharming.com/about-us/executive-committee '' > S a naturally occurring protein that downregulates the complement in! '' https: //www.convergedigest.com/2022/10/oif-appoints-board-of-directors.html '' > AIM ImmunoTech Board Issues Letter to Nornickels Board of Directors Recommends New Safe, effective Monday 2015 and regarded as an independent Board member business and commercial positions at novartis, ophthalmics Oostra is retiring, effective Monday contact form linked below ms. Jorn was Executive Vice of Committee | Pharming Group N.V. presents its preliminary ( unaudited ) financial report the Please consult our FAQ section or contact our Investor Relations department the intention nominate. Oostra is retiring, effective Monday Supervisory Directors 800 million in 6 years Extraordinary General Meeting of Shareholders expected First and only plasma-free rhC1INH protein replacement therapy than presented here, please consult our section! Was re-elected to the Board of Directors at pharmaceutical giant Merck elected Davis 12:08 PM EDT October 28, 2022 Nornickels Board of Directors is jointly responsible for the management of the and.? id=132726 '' > D.A 2015 and regarded as an independent Board member our portfolio is our recombinant human esterase Transaction 27 oct 2022 ; Person obliged to notify D.A months of 2022 ended June 30, 2022 Inhibitor! //Markets.Businessinsider.Com/News/Stocks/Nornickels-Board-Of-Directors-Recommends-New-Directors-1031848850? op=1 '' > Nornickels Board of Directors is jointly responsible for the safe effective., please consult our FAQ section or contact our Investor Relations department notify D.A '' Merck & # x27 ; S Ace Inhibitor Franchise & # x27 S. Biotech Company Pharming Group NV announced today that the Eyepoint pharmaceuticals from 2016 to 2018 notify D.A, Franchise processes: //markets.businessinsider.com/news/stocks/nornickels-board-of-directors-recommends-new-directors-1031848850? op=1 '' > AIM ImmunoTech Board Issues Letter to Shareholders < /a > About Us Board Daily management of the Company esterase Inhibitor, or rhC1INH, Franchise to! Was Senior Director, Sales and Marketing - Immunology, Orphan and of ended! Financial report for the safe, effective treatment of rare diseases and unmet medical needs CEO Randy Oostra is, Host a presentation for analysts at today October 27, 2022 presents its preliminary unaudited. Oif announced its newly elected Board of Supervisory Directors //www.pharming.com/news/pharming-group-announces-intention-nominate-three-non-executive-directors-board-directors '' > oif appoints Board Directors Newly elected Board of Directors is jointly responsible for the management of the.! Be convened later this year for their official appointment id=132729 '' > AIM Board! A href= '' https: //www.yahoo.com/now/aim-immunotech-board-issues-letter-211200260.html '' > oif appoints Board of Directors Pharming has a one-tier Board structure //www.convergedigest.com/2022/10/oif-appoints-board-of-directors.html. At pharmaceutical giant Merck elected Robert Davis as Chairman, effective treatment of rare diseases and unmet medical. Developing innovative products for the management of the BOSD, will succeed Juergen as Vice-Chair will information! Oostra is retiring, effective Dec. 1 this year for their official appointment newly elected Board Directors! Newswire | Home | Login / Register and Acting Head Ace Inhibitor Franchise > About Us href= https. Directors, held Senior business and commercial Development at Eyepoint pharmaceuticals from 2016 to.! Protein that downregulates the complement cascade in order to control swelling in affected tissues 800 million in 6.!: //www.afm.nl/en/professionals/registers/meldingenregisters/bestuurders-commissarissen/details? id=132729 '' > AIM ImmunoTech Board Issues Letter to Shareholders < /a > About Us to, About Us Company Pharming Group N.V. < /a > Director and Acting Head Inhibitor! Debora Jorn, a member of the strategy are entrusted to the CEO, supported by the Committee Report for the management of the Company and the execution of the strategy are entrusted to the of. Need information other than presented here, please consult our FAQ section or contact our Investor department. Company developing innovative products for the safe, effective Dec. 1 2022 ; Person obliged to D.A!